Soybean protein-derived peptides inhibit inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPK-JNK and NF-kappa B activation

被引:42
|
作者
Yi, Guofu [1 ]
Li, He [1 ]
Liu, Menglan [1 ]
Ying, Zhiwei [1 ]
Zhang, Jian [1 ]
Liu, Xinqi [1 ]
机构
[1] Beijing Technol & Business Univ BTBU, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing Engn & Technol Res Ctr Food Addit, Beijing, Peoples R China
关键词
inflammation; MAPK-JNK; NF-kappa B; RAW264; 7; cells; soybean protein-derived peptides (SBP); TRL4; EXPRESSION; TARGET; IDENTIFICATION; PRESSURE; BLOCKADE; SUBUNITS; COMPLEX; GENE;
D O I
10.1111/jfbc.13289
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to determine the effect of soybean protein-derived peptides (SBP) on the inhibition of lipopolysaccharide (LPS)-induced RAW264.7 cell inflammation. The mRNA of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), Lymphocyte Antigen 96 (LY96), and nuclear factor-kappa B (NF-kappa B) were detected with RT-qPCR. The concentrations of cytokines (TNF-alpha, IL-6, and IL-1 beta) secreted were detected by ELISA Kit. The results indicated that SBP inhibited the inflammatory stress induced by LPS in RAW264.7 cells. Western blot analysis was used to examine this anti-inflammatory molecular mechanism. The findings showed that SBP impeded the increase of toll-like receptor 4 activity by restricting LY96, while also inhibiting the mitogen-activated protein kinase-c-Jun N-terminal kinase pathway in cells, as well as LPS-induced NF-kappa B activation caused by the degradation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (I kappa B alpha). Consequently, the release of pro-inflammatory cytokines (TNF-alpha, IL-6, and IL-1 beta) was inhibited, preventing LPS-induced inflammation of RAW 264.7 cells. Therefore, this research highlighted the potential application of SBP in the development of anti-inflammatory foods that prevented inflammatory-immune diseases. Practical applications Inflammation is the root cause of almost all pathology and is related to many human diseases, including arthritis, obesity, cancer and atherosclerosis. Therefore, the development of products that can regulate and intervene inflammation has a broad application prospect. Soybean protein and soybean peptide have many functional properties, including immunoregulation, anti-inflammatory, anti-oxidation and so on. However, there are still some shortcomings in the development of soy protein supplements, such as solubility and absorption. Compared with soybean protein, derived peptide is easy to digest, and has high solubility. As a good nutritional supplement, the nutritional support of soybean protein-derived peptides may help to reduce inflammation and improve the level of cytokines combined with drugs.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Sulfated Derivative of 20(S)-Ginsenoside Rh2 Inhibits Inflammatory Cytokines Through MAPKs and NF-kappa B Pathways in LPS-Induced RAW264.7 Macrophages
    Bi, Wen-Yan
    Fu, Ben-Dong
    Shen, Hai-Qing
    Wei, Qian
    Zhang, Cui
    Song, Zhou
    Qin, Qian-Qian
    Li, Hui-Ping
    Lv, Shuang
    Wu, Shuai-Cheng
    Yi, Peng-Fei
    Wei, Xu-Bin
    INFLAMMATION, 2012, 35 (05) : 1659 - 1668
  • [42] Roxatidine Suppresses Inflammatory Responses Via Inhibition of NF-κB and p38 MAPK Activation in LPS-Induced RAW 264.7 Macrophages
    Cho, Eu-Jin
    An, Hyo-Jin
    Shin, Ji-Sun
    Choi, Hye-Eun
    Ko, Jane
    Cho, Young-Wuk
    Kim, Hyung-Min
    Choi, Jung-Hye
    Lee, Kyung-Tae
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (12) : 3648 - 3659
  • [43] Sulfated Derivative of 20(S)-Ginsenoside Rh2 Inhibits Inflammatory Cytokines Through MAPKs and NF-kappa B Pathways in LPS-Induced RAW264.7 Macrophages
    Wen-Yan Bi
    Ben-Dong Fu
    Hai-Qing Shen
    Qian Wei
    Cui Zhang
    Zhou Song
    Qian-Qian Qin
    Hui-Ping Li
    Shuang Lv
    Shuai-Cheng Wu
    Peng-Fei Yi
    Xu-Bin Wei
    Inflammation, 2012, 35 : 1659 - 1668
  • [44] Chelidonine suppresses LPS-Induced production of inflammatory mediators through the inhibitory of the TLR4/NF-κB signaling pathway in RAW264.7 macrophages
    Liao, Wang
    He, Xiaojie
    Yi, Zhuwen
    Xiang, Wei
    Ding, Yan
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 : 1151 - 1159
  • [45] Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells
    Wenzhi Hu
    Xiangjun Yang
    Cao Zhe
    Qin Zhang
    Lie Sun
    Kejiang Cao
    Pharmacological Reports, 2011, 63 : 781 - 789
  • [46] Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells
    Hu, Wenzhi
    Yang, Xiangjun
    Zhe, Cao
    Zhang, Qin
    Sun, Lie
    Cao, Kejiang
    PHARMACOLOGICAL REPORTS, 2011, 63 (03) : 781 - 789
  • [47] Effects of Baimuxinol on the inflammation and oxidative stress of LPS-induced RAW264.7 macrophages via regulating the NF-ΚB/IΚBα and Nrf2/ARE signaling pathway
    Chen, Yan
    Chen, Nan
    Wang, Jing
    Li, Shuqing
    ACTA BIOCHIMICA POLONICA, 2023, : 77 - 82
  • [48] Preventive effects of matrine on LPS-induced inflammation in RAW 264.7 cells and intestinal damage in mice through the TLR4/NF-κB/ MAPK pathway
    Mao, Ningning
    Yu, Yaming
    Lu, Xuanqi
    Yang, Yang
    Liu, Zhenguang
    Wang, Deyun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [49] Regulation of LPS-Induced Inflammatory Responses in Bovine Mammary Epithelial Cells via TLR4-Mediated NF-κB and MAPK Signaling Pathways by Lactoferrin
    Zhang, Kai
    Zhang, Ruizhen
    Zhang, Yuanyuan
    Zhang, Min
    Su, Hong
    Zhao, Feifei
    Wang, Daqing
    Cao, Guifang
    Zhang, Yong
    LIFE-BASEL, 2025, 15 (01):
  • [50] Macleaya cordata Extract Inhibits LPS-Induced IPEC-J2 Inflammation Through TLR4-Mediated NF-κB and MAPK Signaling Pathways
    Han, Diangang
    Yang, Hongqing
    Che, Litao
    Zhang, Chong
    Li, Jing
    Ye, Lingling
    Zhang, Chunyong
    Guo, Rongfu
    Xin, Jige
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (04)